利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.027 秒)

    Controlling attention and memory by altering neuronal carbonic anhydrase activity
    1.
    发明授权
    Controlling attention and memory by altering neuronal carbonic anhydrase activity 失效

    公开(公告)号：US06552053B2

    公开(公告)日：2003-04-22

    申请号：US09875283

    申请日：2001-06-07

    申请人： Miao-Kun Sun ,  Daniel L. Alkon ,  Wei-Qin Zhao

    发明人： Miao-Kun Sun ,  Daniel L. Alkon ,  Wei-Qin Zhao

    IPC分类号： A61K3141

    CPC分类号： A61K31/00 ,  A61K31/433

    摘要： The invention provides a method for modulating attentive cognition comprising administering a compound that alters intraneuronal carbonic anhydrase activity thereby affecting establishment of a theta rhythm. The metabolic pathway of the compound preferably involves bicarbonate-mediated GABAergic depolarization. The term “attentive cognition” is meant to encompass memory formation, learning, spatial memory, and attention. The modulating may be stimulating, or the compound may have the multiple effects of inhibiting intraneuronal carbonic anhydrase activity, establishment of a theta rhythm, and memory acquisition. The invention further provides a method of modulating memory and attention comprising switching theta rhythm on and off, the switching comprising potentiating or inhibiting intraneuronal carbonic anhydrase activity.

    TREATMENT OF COGNITIVE DISORDERS ASSOCIATED WITH ABNORMAL DENDRITIC SPINES USING PKC ACTIVATORS
    4.
    发明申请
    TREATMENT OF COGNITIVE DISORDERS ASSOCIATED WITH ABNORMAL DENDRITIC SPINES USING PKC ACTIVATORS 有权
    使用PKC激活剂治疗与异常脱发性脊髓相关的认知障碍

    公开(公告)号：US20130331444A1

    公开(公告)日：2013-12-12

    申请号：US13817040

    申请日：2011-08-19

    申请人： Miao-kun Sun ,  Daniel L. Alkon

    发明人： Miao-kun Sun ,  Daniel L. Alkon

    IPC分类号： A61K31/365

    CPC分类号： A61K31/365

    摘要： The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.

    摘要翻译： 本公开提供使用PKC激活剂治疗与异常树突棘相关的认知障碍（例如脆性X综合征，脆性X相关震颤/共济失调综合征，自闭症或智力迟钝）的方法。

    THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY
    5.
    发明申请
    THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY 审中-公开
    BRYOSTATINS，BRYOSS，和其他相关物质对异位/诱导性记忆损伤和脑损伤的治疗效果

    公开(公告)号：US20130165453A1

    公开(公告)日：2013-06-27

    申请号：US13553565

    申请日：2012-07-19

    申请人： Miao-Kun Sun ,  Daniel L. Alkon

    发明人： Miao-Kun Sun ,  Daniel L. Alkon

    IPC分类号： A61K31/365 ,  A61K31/194

    CPC分类号： A61K31/05 ,  A61K31/00 ,  A61K31/335 ,  A61K31/35 ,  A61K31/365 ,  A61K31/395 ,  A61K31/4015 ,  A61K38/00 ,  A61K38/1825

    摘要： The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.

    摘要翻译： 本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）的促进剂，脑源性神经营养因子（BDNF）或其他神经营养因子来治疗中风。 具体地说，本发明提供治疗中风的方法，其包括以下步骤：鉴定遭受中风的个体，并向所述受试者施用一定量的包含蛋白激酶C（PKC）激活剂或4-甲基儿茶酚乙酸（MCBA）的药物组合物， 和有效治疗中风的至少一种症状的药学上可接受的载体。

    Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury
    7.
    发明申请
    Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury 审中-公开
    苔藓抑制素，苔藓植物和其他相关物质对缺血/卒中诱发的记忆障碍和脑损伤的治疗作用

    公开(公告)号：US20090036514A1

    公开(公告)日：2009-02-05

    申请号：US12068732

    申请日：2008-02-11

    申请人： Miao- Kun Sun ,  Daniel L. Alkon

    发明人： Miao- Kun Sun ,  Daniel L. Alkon

    IPC分类号： A61K31/365 ,  A61K31/352 ,  A61K31/4015 ,  A61P9/10

    CPC分类号： A61K31/05 ,  A61K31/00 ,  A61K31/335 ,  A61K31/35 ,  A61K31/365 ,  A61K31/395 ,  A61K31/4015 ,  A61K38/00 ,  A61K38/1825

    摘要： The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.

    摘要翻译： 本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）的促进剂，脑源性神经营养因子（BDNF）或其他神经营养因子来治疗中风。 具体地说，本发明提供治疗中风的方法，其包括以下步骤：鉴定遭受中风的个体，并向所述受试者施用一定量的包含蛋白激酶C（PKC）激活剂或4-甲基儿茶酚乙酸（MCBA）的药物组合物， 和有效治疗中风的至少一种症状的药学上可接受的载体。

    Synergistic enhancement of cognitive ability
    9.
    发明授权
    Synergistic enhancement of cognitive ability 有权
    协同增强认知能力

    公开(公告)号：US06821979B2

    公开(公告)日：2004-11-23

    申请号：US10172005

    申请日：2002-06-17

    申请人： Daniel L. Alkon ,  Miao-Kun Sun

    发明人： Daniel L. Alkon ,  Miao-Kun Sun

    IPC分类号： A61K3152

    CPC分类号： A61K31/417 ,  A61K31/135 ,  A61K31/198 ,  A61K31/4172 ,  A61K31/52 ,  A61K2300/00

    摘要： The present invention relates to the combination of a methylxanthine and a carbonic anhydrase activator to provide synergistic effects. The invention further relates to the improved/enhanced cognitive ability of individuals, particularly those suffering from various disorders, such as Alzheimer's Disease, stroke, hypoxia, general dementia, ADHD, mental retardation, and “sun down” syndrome.

    摘要翻译： 本发明涉及甲基黄嘌呤和碳酸酐酶活化剂的组合以提供协同效应。 本发明还涉及个体，特别是患有诸如阿尔茨海默氏病，中风，缺氧，一般性痴呆，ADHD，智力低下和“下垂”综合症等各种疾病的个体的改善/增强的认知能力。

    Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease
    10.
    发明申请
    Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease 审中-公开
    磷酸酶2A（PP2A）用于阿尔茨海默病诊断和治疗的异常

    公开(公告)号：US20090029355A1

    公开(公告)日：2009-01-29

    申请号：US11660868

    申请日：2004-11-15

    申请人： Wei-Qin Zhao ,  Daniel L. Alkon

    发明人： Wei-Qin Zhao ,  Daniel L. Alkon

    IPC分类号： C12Q1/68 ,  C12Q1/42 ,  G01N33/53 ,  C07K16/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/6896

    摘要： This invention relates to methods of diagnosing Alzheimer's disease and methods of screening for compounds for the treatment or prevention of Alzheimer's disease. The methods are based upon newly discovered differences in protein phosphatase 2A (PP2A) function and related molecular events in Alzheimer's disease cells compared to control cells. In one embodiment, differences in basal PP2A gene expression in Alzheimer's cells are compared to controls. In another embodiment differences in PP2A protein and enzyme activity are compared in test and control cells. In another embodiment differences in response to substances that inhibit PP2A function are compared. Still another embodiment detects differences in the subcellular distribution of phosphorylated Erk1/2, a substrate of PP2A, in normal and Alzheimer's disease cells. The detection of Alzheimer's disease-specific differences in PP2A function and related events in peripheral tissues provides the basis for highly practical and efficient tests and diagnostic test kits for the early diagnosis of Alzheimer's disease, as well as providing a biochemical basis for identifying therapeutic targets for drug development.

    摘要翻译： 本发明涉及诊断阿尔茨海默病的方法和筛选用于治疗或预防阿尔茨海默病的化合物的方法。 该方法基于新发现的蛋白磷酸酶2A（PP2A）功能和阿尔茨海默病细胞相关分子事件与对照细胞相比的差异。 在一个实施方案中，将阿尔茨海默氏病细胞中基础PP2A基因表达的差异与对照进行比较。 在另一个实施方案中，在测试和对照细胞中比较了PP2A蛋白质和酶活性的差异。 在另一个实施方案中，比较了抑制PP2A功能的物质的反应差异。 另一个实施方案检测正常和阿尔茨海默氏病细胞中磷酸化Erk1 / 2（PP2A底物）的亚细胞分布的差异。 检测外周组织中PP2A功能和相关事件中的阿尔茨海默病特异性差异为高龄实用和有效的测试和诊断试剂盒提供了基础，用于早期诊断阿尔茨海默氏病，并为确定治疗靶点提供了生物化学依据 药物开发。